The potential of nearly 300 next generation immune checkpoint modulators for the treatment (Roots Analysis)

Over time, significant strides have been made in immune checkpoint research, resulting in the discovery of several inhibitory (LAG-3, TIM-3, TIGIT, VISTA and B7-H3) and stimulatory receptors (OX40, ICOS, GITR, 4-1BB and CD40), which are being investigated as potential targets for therapy development. Further, studies of combinatorial immune checkpoint blockade / co-stimulation, targeting newly identified checkpoints along with known checkpoint inhibitor therapies, have demonstrated promising clinical outcomes as well.

Key Inclusions

• A detailed assessment of the current market landscape, including information on drug developer(s), phase of development (marketed, clinical and preclinical / discovery stage) of lead candidates, target immune checkpoints, their respective mechanisms of action (inhibitory or stimulatory), type of therapeutic modality used (monoclonal antibody, antibody fragment, small molecule and others), route of administration (intravenous, subcutaneous, oral and others), target disease indication, target therapeutic area and type of therapy (monotherapy, combination therapy and both).
• A detailed analysis of more than 590 completed, ongoing and planned clinical studies of next generation immune checkpoint inhibitors and stimulators, highlighting prevalent trends across various relevant parameters, such as current trial status, trial registration year, phase of development, study design, leading industry sponsors / collaborators (in terms of number of trials conducted), trial focus, type of target, target indication(s), target therapeutic area(s), enrolled patients population and regional distribution.
• Detailed profiles of developers of next generation immune checkpoint modulators (shortlisted on the basis of the number of pipeline products), featuring an overview of the company, its financial information (if available), a detailed description of its product portfolio and recent collaborations. In addition, each profile includes an informed future outlook.
• An in-depth analysis of more than 490 grants that have been awarded to research institutes engaged in next generation immune checkpoint therapy-related projects, in the period between 2016 and 2019 (till November), including analysis based on important parameters, such as year of grant award, amount awarded, administration institute center, funding institute center, support period, type of grant application, purpose of grant award, grant mechanism, popular target immune checkpoints, responsible study section, focus area, prominent program officers, and type of recipient organizations. It also features a detailed analysis based on the types of target immune checkpoints and therapeutic areas, along with a multivariate grant attractiveness analysis based on parameters, such as grant amount, support period, type of grant application and number of disease indications under investigation.
• An analysis of the partnerships that have been established in the recent past, covering R&D collaborations, licensing agreements (specific to affiliated technology platforms and product candidates), product development and commercialization agreements, clinical trial agreements, manufacturing agreements, mergers and acquisitions, manufacturing and service agreements, and other relevant types of deals.
• An insightful competitiveness analysis of biological targets, featuring a [A] three-dimensional bubble representation that highlights the targets that are being evaluated for next generation immune checkpoint therapy development, taking into consideration the number of lead molecules based on a particular target, phase of development of candidate therapies, number of grants and number of publications [B] a five-dimensional spider-web analysis, highlighting the most popular immune checkpoint targets.

An analysis of the big biopharma players engaged in this domain, featuring a heat map based on parameters, such as number of therapies under development, target disease indications, partnership activity and target portfolio

 

To order this 350+ page report, which features 140+ figures and 170+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/immune-checkpoint-inhibitors/303.html

 

The USD 12 billion (by 2030) financial opportunity within the next generation immune checkpoint modulators market has been analyzed across the following segments:

• Target Disease Indication
• Breast Cancer
• Chronic Lymphocytic Leukemia
• Colorectal Cancer
• Head and Neck Cancer
• Lung Cancer
• Lupus Nephritis
• Melanoma
• Multiple Myeloma
• Primary Sjögren's Syndrome
• Others

 

• Target Immune Checkpoint
• B7-H3
• CD38
• CD40
• CD47
• Others

 

• Mechanism of Action
• Inhibitory
• Stimulatory

 

• Therapeutic Modality
• Monoclonal Antibody
• Small Molecule

 

• Type of Therapy
• Monotherapy
• Combination Therapy

 

• Route of Administration
• Intravenous
• Subcutaneous
• Others

 

• Key Geographical Regions
• North America
• Europe
• Asia-Pacific and the Rest of the World

 

The Next Generation Immune Checkpoint Inhibitors and Stimulators Market, 2020-2030. report features the following companies, which we identified to be key players in this domain:

• Bristol Myers Squibb
• GlaxoSmithKline
• Incyte
• Novartis
• Trillium Therapeutics

 

Table of Contents

 

1. Preface

2. Executive Summary

3. Introduction
 

4. Current Market Landscape: Clinical and Preclinical Molecules
 

5. Market Landscape: Therapies Targeting Cd47
 

6. Market Landscape: Therapies Targeting 4-1bb
 

7. Clinical Trial Analysis
 

8. Company Profiles: Next Generation Inhibitors and Stimulators
 

9. Academic Grants Analysis
 

10. Partnerships and Collaborations
 

11. Target Competitiveness Analysis
 

12. Big Pharma Initiatives
 

13. Market Forecast and Opportunity Analysis
 

14. Concluding Remarks

 

15. Executive Insights

 

16. Appendix 1: Tabulated Data

 

17. Appendix 2: List of Companies and Organizations

 

To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/immune-checkpoint-inhibitors/303.html

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

[email protected]